IRIDEX CORPORATION (NASDAQ:IRIX) Files An 8-K Results of Operations and Financial Condition

Item 2.02.

On January 9, 2017, the Company announced its anticipated
revenues for the fourth quarter and full year ended December 31,
2016. A copy of the Companys press release announcing such
results dated January 9, 2017 is attached hereto as Exhibit 99.1.

This information shall not be deemed filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act), or incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange
Act, except as shall be expressly set forth by specific reference
in such a filing

About IRIDEX CORPORATION (NASDAQ:IRIX)

IRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Company operates through ophthalmology segment. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes, and are used in the treatment of serious eye diseases, including the over three causes of irreversible blindness, such as diabetic retinopathy, glaucoma and age-related macular degeneration (AMD). In addition, the Company’s ophthalmology products are often used in vitrectomy procedures (used to treat proliferative diabetic retinopathy, macular holes, retinal tears and detachments), which are generally performed in the operating room and require a consumable single use intraocular laser probe (EndoProbe) to deliver light to the back of the eye together with other instrumentation.

IRIDEX CORPORATION (NASDAQ:IRIX) Recent Trading Information

IRIDEX CORPORATION (NASDAQ:IRIX) closed its last trading session up +0.13 at 13.87 with 47,624 shares trading hands.